What to Expect Following Diagnosis
Produced in collaboration with GBS|CIDP Foundation International
Support for this patient education program was provided by Takeda.
Multifocal Motor Neuropathy (MMN) affects about 1-2 in every 100,000 individuals worldwide. When people develop MMN, their motor nerves are attacked by their immune system. This results in weakness and muscle wasting, and tremendous negative impacts on quality of life and ability to perform daily tasks. Sensation, however, is not affected by MMN.
During this program, patients with MMN and their caregivers will learn about the condition, its treatments and what they can do to continue performing their daily tasks. The faculty panel share their expert opinions to help people with MMN, their caregivers, and those who suspect they may have MMN, communicate with their doctors, to improve diagnosis and make the best decisions regarding their management strategies.
Dr. Peter Donofrio, MD
Peter D. Donofrio is a graduate of the University of Notre Dame and the Ohio State University School of Medicine. He completed his residencies at Good Samaritan Hospital in Cincinnati and the University of Michigan. He pursed a neuromuscular fellowship at Michigan, where he subsequently was on faculty for 4 years. He was recruited to Wake Forest University in 1986 where he stayed for 20 years before moving to Vanderbilt University in 2006. He is a Professor of Neurology at Vanderbilt University Medical Center. He has a special interest in Guillain-Barre Syndrome, CIDP, other forms of neuropathy, ALS and myasthenia gravis. He is the author of more than 200 manuscripts, book chapters, abstracts, and monographs. He is on the Board of Directors of the GBS/CIDP Foundation. He has served as the President of the American Association of Neuromuscular and Electrodiagnostic Medicine and has served on several committees of the American Academy of Neurology. He is active in patient care, teaching and education.
GBS|CIDP Foundation International
Lisa Butler is the executive director of the GBS/CIDP Foundation International in Narberth, Pennsylvania. Ms Butler has a 10-year career in marketing and event planning for nonprofit organizations. Before assuming her current position as executive director, she managed the Foundation’s marketing and development programs, and was recognized by Patient Services, Inc. (PSI) with the 2016 Extraordinary Support Award. Ms Butler first of learned of the Foundation in 1992 (prior to joining the staff in 1993) when her father-in-law was diagnosed with Guillain-Barre syndrome (GBS).Ten years later, her son, Stuart, was diagnosed with GBS. Following Stuart’s recovery, she became the parent liaison for the Foundation for “parents with children diagnosed with GBS”.
Michelle Greer RN, IGCN, Nufactor
Michelle Greer is the Senior Vice President in charge of sales for Nufactor. She has over 20 years of experience with plasma administration, management and sales. Michelle has strong national relationships with key opinion leaders in the autoimmune and immune deficiency arena. She has a proven record of business growth and development through education and working with clients to understand standards of care, as well as payer policies. Michelle represents NuFactor as a member of the GBS-CIDP Foundation International Specialty Pharmacy Advisory Board.
Brenda Perales is a part-time MMN Advocate in Leesburg Virginia who was diagnosed with MMN in 2012. Not uncommonly, at the start of her journey she was thought to have ALS until a positive response to her first IVIG treatment indicated she had MMN instead. She continued on IVIG every three weeks for about two years, but the pronounced side effects of IVIG continued to make day to day life difficult for her. She made the switch to SubQ six years ago in hopes that it could improve her quality of life, and the results have exceeded her expectations. Brenda currently serves as a liaison for the GBS CIDP Foundation for those newly diagnosed with MMN, and works on the foundation's strategic planning committee to improve Patient Services for patients and caregivers dealing with GBS, CIDP and variants. In the past, she has advocated for legislation to support IVIG home infusion for patients with CIDP or MMN and supported PPTA on Plasma Awareness Day in Washington DC. She has spoken at the Pfizer Rare Disease summit to share her story with with those in all aspects of the industry and to help put a face to the patients they're aiding. Most recently, she just signed on to be an MMN Ambassador for Takeda in the UK to increase MMN awareness in the region and to help others who have also been diagnosed.